Lipocine Stock (NASDAQ:LPCN), Trade Ideas

Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABVC

ALGN

ASPS

ASXC

BHVN

CLBK

CROX

CTCX

EBAY

ENVX

EOLS

FEMY

FFWM

IMAX

INPX

INSG

KLAC

LIXT

LPCN

LRCX

MRSN

NOVA

NVCR

OSTK

OTLY

PRFT

SHYF

SIMO

TNET

TPIC

TREE

TTNP

ULBI

VIEW

WRNT

YELL

Gainers


	Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.


Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Biotech

Health Care

General

Lipocine Inc (NASDAQ: LPCN) shares are trading higher after the company released topline results from a Phase 2 clinical study of LPCN 1148, an oral candidate under development for the 

Why Lipocine Stock Is Moving Higher Today?

ABST

ACVA

ADSE

AMPE

BBIG

BBLN

BFLY

BNMV

BPTS

BYND

CDRO

CLSK

CPRX

DADA

DYNT

ENTG

GFAI

GRIL

GRPN

IBRX

IMBI

INTZ

JAGX

KLXE

MANU

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MGNI

MINM

MTNB

MXCT

NEPT

ORGO

PACW

PHAR

POLA

PRPL

SBFM

SMRT

SONO

TIVC

VATE

VCIG

VYNT

ZURA

Gainers


	Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.


Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Lipocine Inc

<h3>Gainers</h3>
<ul>
<li>Eliem Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock increased by 49.07% to $2.43. The company's market cap stands at $91.8 million. </li>
<li>Alpine Immune Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>) shares rose 36.62% to $64.27. The company's market cap stands at $4.2 billion. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 22.41% to $3.44. The market value of their outstanding shares is at $3.9 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 15.3% to $1.77. The market value of their outstanding shares is at $8.2 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock rose 15.2% to $7.5. The market value of their outstanding shares is at $39.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 55.0% to $1.08 during Thursday's pre-market session. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.34% to $1.82. The company's market cap stands at $5.1 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) shares decreased by 10.96% to $0.78. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 10.25% to $1.84. The market value of their outstanding shares is at $2.4 million. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) shares decreased by 9.98% to $13.0. The company's market cap stands at $334.1 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock declined by 9.79% to $0.44. The market value of their outstanding shares is at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

ALPN

APVO

BACK

CYCC

ELYM

HCTI

RCEL

RLYB

SCNI

SILO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Lipocine shares are trading higher after the company announced trial data showing LPCN 2401 treatment resulted in statistically significant body composition improvement in men.

Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity

Lipocine Announces Week 52 Results From LPCN 1148 Phase 2 Study In Patients With Cirrhosis; Says Met Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study

Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, oral brexanolone, is being developed by Lipocine for the treatment of postpartum depression (PPD).

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

<h3>Gainers</h3>
<ul>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 18.54% to $0.76. The market value of their outstanding shares is at $6.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock rose 11.75% to $4.84. The company's market cap stands at $25.0 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares moved upwards by 10.49% to $0.83. The company's market cap stands at $22.5 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 9.99% to $1.21. The market value of their outstanding shares is at $17.8 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares increased by 9.87% to $1.78. The company's market cap stands at $50.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock declined by 75.2% to $1.29 during Wednesday's after-market session. The market value of their outstanding shares is at $52.5 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock fell 9.1% to $0.59. The market value of their outstanding shares is at $21.0 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 8.58% to $0.38. The market value of their outstanding shares is at $20.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 7.9% to $5.6. The market value of their outstanding shares is at $72.8 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares declined by 7.48% to $0.26. The company's market cap stands at $47.8 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock declined by 7.1% to $4.45. The company's market cap stands at $23.6 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

CYTH

EVOK

GLTO

MIRA

NCNA

SPRB

12 Health Care Stocks Moving In Wednesday's After-Market Session

<ul>
<li>Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study</li>
<li>On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing&nbsp;</li>
</ul>
SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).
PPD is a major depressive disorder with onset either during pregnancy or within four weeks of delivery, with symptoms persisting for up to 12 months after childbirth.&nbsp; There is an unmet need for an oral fast-acting product with an improved efficacy and safety profile to treat PPD. Oral LPCN 1154 comprising a bioidentical neuroactive steroid with 48-hour outpatient dosing is targeted to provide rapid relief with robust efficacy. &nbsp;
Lipocine has previously confirmed with the U.S. Food and Drug Administration (FDA) acceptance of a proposal for a 505(b)(2) NDA filing based on a single pivotal study comparing exposure of LPCN 1154 with the approved IV infusion of brexanolone.&nbsp; Following a successful meeting with the FDA, Lipocine reached agreement on the use of exposure parameters and criteria to assess comparable exposure to IV infusion&nbsp;brexanolone.
Based on positive results of the 2023 multi-arm crossover pilot PK study, Lipocine recently completed a single arm PK study (N=8) utilizing the "to be marketed" formulation and target dosing regimen. PK exposure results of the "to be marketed" scaled up formulation were consistent with the PK performance of pilot study clinical formulation. &nbsp;Furthermore, the exposure PK parameters observed in this study are comparable to those of IV infusion brexanolone administered per label instructions in the pilot study. There were no serious or severe adverse events observed in this single arm, multi-dose study, and a single report of asymptomatic, moderate decrease of oxygen saturation.&nbsp; Consistent with the goal of NDA submission by the end of the fourth quarter of 2024, the company anticipates top line results late in the second quarter of 2024 from the crossover pivotal study of LPCN 1154 with the reference product IV brexanolone.
"We believe these results support the design of&nbsp;the planned NDA enabling pivotal study," said Dr.&nbsp;Mahesh Patel, President and CEO of Lipocine.&nbsp; "LPCN 1154 is targeted to be a highly effective, oral, fast-acting and short duration treatment option for PPD, a serious and potentially life-threatening condition. We believe a 48-hour oral dosing duration will be important for patients and caregivers. &nbsp;If approved, LPCN 1154 has the potential to be a differentiated preferred treatment option for PPD."
About&nbsp;LPCN 1154
LPCN 1154 is an oral formulation of brexanolone in development targeted for administration resulting in rapid relief of postpartum depression (PPD). Brexanolone is a bioidentical to naturally occurring neuro active steroid, allopregnanolone,&nbsp;a positive allosteric modulator of y-aminobutyric acid (GABA) receptor.&nbsp;LPCN 1154 is expected to have characteristics that could be particularly appealing to patients with severe PPD, acutely elevated suicide risk, and in whom rapid improvement&nbsp;is a priority while presenting no significant risk of adverse reactions to breastfed infants from exposure to brexanolone.

Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares rose 43.4% to $0.27 during Thursday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock moved upwards by 33.64% to $1.43. The company's market cap stands at $83.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares rose 24.82% to $122.0. The market value of their outstanding shares is at $954.9 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 20.33% to $0.38. The market value of their outstanding shares is at $11.3 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares increased by 18.7% to $4.57. The company's market cap stands at $24.2 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock rose 16.0% to $1.68. The market value of their outstanding shares is at $72.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock fell 50.5% to $0.05 during Thursday's pre-market session. The company's market cap stands at $4.0 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) shares fell 34.16% to $22.0. The company's market cap stands at $1.0 billion. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares decreased by 18.29% to $0.22. The market value of their outstanding shares is at $5.4 million. </li>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock declined by 14.24% to $384.0. The market value of their outstanding shares is at $47.2 billion. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock fell 12.07% to $1.53. The market value of their outstanding shares is at $131.2 million. </li>
<li>Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) stock decreased by 9.76% to $3.61. The market value of their outstanding shares is at $158.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAG

ARAV

ATRC

CELU

KRON

LUCD

MESO

PCSA

TBIO

ZJYL

<ul>
<li>Lipocine to receive $11 million license fee</li>
<li>Up to $259 million in development and commercial sales milestones</li>
<li>Tiered royalties on net sales of licensed products up to 18%</li>
<li>Commercialization of TLANDO transitions to Verity Pharma effective Feb.1 2024</li>
<li>Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally</li>
</ul>
SALT LAKE CITY, Jan. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO&#xAE; in the United States and, if approved, in Canada.&nbsp; TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.&nbsp;The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next generation, once daily oral product candidate for TRT.
Under the terms of the agreement, Lipocine will receive from Verity Pharma a license fee of $11 million with an initial payment of $2.5 million which was received on signing of the License Agreement, $5 million to be paid on February 1, 2024, $2.5 million to be paid no later than January 1, 2025, and $1 million to be paid no later than January 1, 2026. Lipocine will be entitled to receive up to $259 million in development and sales-based commercial milestone payments, as well as tiered royalty payments at rates ranging from 12% up to 18% on net sales of TLANDO franchise products.&nbsp; Under the agreement, Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, and all further development.&nbsp; Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally.
"We are very pleased to enter this license agreement with Verity Pharma. Men's health is one of Verity Pharma's areas of focus and Verity Pharma's sales force has existing relationships with men's health prescribers. Verity Pharma is highly motivated and has the capabilities and expertise to successfully grow the TLANDO franchise without interruption in patient access to TLANDO," said Dr.&nbsp;Mahesh Patel, President and Chief Executive Officer of Lipocine.&nbsp;"This transaction will further enable Lipocine's strategy to focus on developing treatments for CNS disorders and to add value to our non-core assets."
TRT is a large and growing market with ~8M annual prescriptions in the U.S. and ~650,000 in Canada.
Raymond James acted as financial advisor to Lipocine on this transaction.
About TLANDO
TLANDO is approved by the FDA as a testosterone replacement therapy ("TRT") in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). It was developed using Lipocine's proprietary Lip'ral drug delivery technology platform.
For full prescribing information, please visit <a href="http://www.tlando.com/">www.TLANDO.com</a>.
IMPORTANT SAFETY INFORMATION
TLANDO (testosterone undecanoate) capsules, for oral use, CIII
Initial U.S. Approval: 1953
IMPORTANT SAFETY INFORMATION
WARNING: BLOOD PRESSURE INCREASES (See Boxed Warning on Product Label for more information)
TLANDO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease.
Before initiating TLANDO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.
Three weeks after initiating therapy monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension.
Re-evaluate whether the benefits of TLANDO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment. Due to this risk, use TLANDO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.
TLANDO INDICATIONS AND USAGE
TLANDO (testosterone undecanoate) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Primary hypogonadism (congenital or acquired)
Hypogonadotropic hypogonadism (congenital or acquired)
LIMITATIONS OF USE
Safety and efficacy of TLANDO in males less than 18 years old have not been established.
CONTRAINDICATIONS
TLANDO is contraindicated in:
Patients with carcinoma of the breast or known or suspected carcinoma of the prostate.
Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman.
Known hypersensitivity to testosterone undecanoate or any of TLANDO's ingredients.
Men with hypogonadal conditions, such as "age-related hypogonadism", that are not associated with structural or genetic etiologies. The efficacy of TLANDO has not been established for these conditions, and TLANDO can increase BP that can increase the risk of MACE.
WARNINGS AND PRECAUTIONS
Increase in Blood Pressure: In Study 18-001, TLANDO increased systolic BP after 4 months of treatment by an average of 4.3 mmHg based on ambulatory blood pressure monitoring (ABPM) and 4.8 mmHg from baseline based on blood pressure cuff measurements [see Adverse Reactions (6.1)].
These BP increases can increase the risk of major adverse cardiovascular events (MACE), with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease.
In some patients, the increase in BP with TLANDO may be too small to detect but can still increase the risk for MACE.
Before initiating TLANDO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. Check BP approximately 3 weeks after initiating TLANDO and periodically thereafter. Treat new-onset hypertension or exacerbations of pre-existing hypertension. Re-evaluate whether the benefits of continued treatment with TLANDO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease.
Polycythemia: Increases in hematocrit levels, reflective of increases in red blood cell mass, may require discontinuation of TLANDO. Check hematocrit prior to initiating TLANDO. Evaluate hematocrit approximately every 3 months during the first year of treatment, and then every 6 months thereafter while the patient is taking TLANDO. If hematocrit becomes elevated, stop TLANDO until hematocrit decreases to an acceptable concentration. If TLANDO is restarted and again causes hematocrit to become elevated, stop TLANDO permanently. An increase in red blood cell mass may increase the risk of thromboembolic events.
Cardiovascular Risk: Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men.
TLANDO can cause BP increases that can increase the risk of MACE. Patients should be informed of this possible risk when deciding whether to use or to continue to use TLANDO.
Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer: Patients with BPH treated with androgens are at an increased risk for worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at increased risk for prostate cancer. Evaluate patients for prostate cancer, including measurement of prostate specific antigen (PSA), prior to initiating and during treatment with androgens.
Venous Thromboembolism: There have been post marketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone replacement products such as TLANDO. Evaluate patients who report symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue TLANDO and initiate appropriate workup and management.
Abuse of Testosterone and Monitoring of Serum Testosterone Concentrations: Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions.
If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.
Not for Use in Women: Due to lack of controlled studies in women and the potential for virilizing effects, TLANDO is not indicated for use in women. Potential for Adverse Effects on Spermatogenesis: With large doses of exogenous androgens, including TLANDO, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) possibly leading to adverse effects on semen parameters including sperm count. Patients should be informed of this possible risk when deciding whether to use or to continue to use TLANDO.
Hepatic Adverse Effects: Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas.&nbsp; TLANDO is not a 17 alpha-alkyl androgen and is not known to produce hepatic adverse effects associated with 17-alpha-alkyl androgens.
Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue TLANDO while the cause is evaluated.
Edema: Androgens, including TLANDO, may promote retention of sodium and water. Edema, with or without congestive heart failure, may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease [see Adverse Reactions (6.1)]. In addition to discontinuation of the drug, appropriate work up and management of edema may be required.
Sleep Apnea: The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases.
Gynecomastia: Gynecomastia may develop and persist in patients being treated for hypogonadism.
Lipid Changes: Changes in serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically after starting testosterone therapy.
Hypercalcemia: Androgens, including TLANDO, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Monitor serum calcium concentrations periodically in these patients.
Decreased Thyroxine-binding Globulin: Androgens, including TLANDO, may decrease concentrations of thyroxin-binding globulins, resulting in decreased total T4 serum concentrations and increased resin uptake of triiodothyronine (T3) and thyroxine (T4). Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
Increases in Prolactin: Increases in serum prolactin have been reported in patients treated with TLANDO in clinical trials. Evaluate serum prolactin levels prior to initiating treatment with TLANDO. Re-evaluate serum prolactin levels 3 to 4 months after starting treatment. If serum prolactin remains elevated, discontinue TLANDO.

Contracts

Global

Lipocine And Verity Pharma Enter Into License Agreement For TLANDO Franchise In The U.S. And Canada; Lipocine To Receive $11M License Fee; Up To $259M In Development And Commercial Sales Milestones

Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes
Patients converting from placebo to LPCN 1148 in the ongoing open label extension also showed improvement in sarcopenia

Lipocine Releases Late Breaking Presentation On LPCN 1148 Phase 2 Results At The Liver Meeting 2023

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1535955/000149315223036494/form8-k.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1535955/000149315223036494/form8-k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1535955/000149315223036494/form8-k.htm</a>

Lipocine Received Notice From Antares Of Antares' Termination Of The License Agreement; Terms Say The License Agreement Will Terminate Effective Jan. 31, 2024

<a href="https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08162023_LPCN_Vandermosten.pdf" title="https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08162023_LPCN_Vandermosten.pdf">https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08162023_LPCN_Vandermosten.pdf</a>

Analyst Ratings

Watching Lipocine Inc.; Zacks Small-Cap Research Sets $40 Price Valuation

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.64) by 6.25 percent. This is a 11.48 percent decrease over losses of $(0.61) per share from the same period last year.

Earnings

Lipocine Q2 EPS $(0.68) Misses $(0.64) Estimate

<h3>Gainers</h3>
<ul>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.</li>
<li>Ultralife Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulbi#NASDAQ">ULBI</a>) shares jumped 43.4% to $7.07 after the company posted better-than-expected second-quarter results.</li>
<li>Mallinckrodt plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mnk#NYSE">MNK</a>) gained 36.5% to $1.7193. Mallinckrodt shares jumped 186% on Wednesday following a report suggesting the company is considering bankruptcy as part of a plan to avoid opioid payments.</li>
<li>North American Construction Group Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noa#NYSE">NOA</a>) jumped 36% to $25.67 following strong quarterly results.</li>
<li>Carmell Therapeutics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctcx#NASDAQ">CTCX</a>) shares gained 33.6% to $4.0087 after the company announced a merger with Axolotl Biologix.</li>
<li>Tupperware Brands Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tup#NYSE">TUP</a>) jumped 33.6% to $2.54.</li>
<li>QuantumScape Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qs#NYSE">QS</a>) rose 30% to $12.24 following quarterly results.</li>
<li>Evolus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eols#NASDAQ">EOLS</a>) gained 27.4% to $9.96 after the company posted upbeat second-quarter sales and raised FY23 revenue forecast.</li>
<li>Lipocine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpcn#NASDAQ">LPCN</a>) jumped 24% to $5.33 after the company reported LPCN 1148 Phase 2 Study met its primary endpoint in patients with cirrhosis.</li>
<li>Overstock.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ostk#NASDAQ">OSTK</a>) rose 22.6% to $38.14 after the company reported upbeat second-quarter results.</li>
<li>Celestica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) shares gained 20.4% to $19.83 after the company announced better-than-expected second-quarter results.</li>
<li>Enovix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envx#NASDAQ">ENVX</a>) shares gained 20% to $23.53 following a narrower-than-expected quarterly loss.</li>
<li>First Foundation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffwm#NASDAQ">FFWM</a>) jumped 18% to $6.69 following upbeat quarterly results.</li>
<li>Align Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/algn#NASDAQ">ALGN</a>) climbed 17.8% to $400.39 following better-than-expected second-quarter earnings.</li>
<li>Nextracker Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxt#NASDAQ">NXT</a>) gained 15.5% to $45.44 following strong quarterly results.</li>
<li>Titan Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttnp#NASDAQ">TTNP</a>) rose 14.3% to $0.6060.</li>
<li>Lixte Biotechnology Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lixt#NASDAQ">LIXT</a>) gained 13.3% to $4.4450. LIXTE Biotechnology recently announced closing of $3.5 million registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) gained 12.7% to $8.59.</li>
<li>The St. Joe Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/joe#NYSE">JOE</a>) surged 11.4% to $60.89 following quarterly results.</li>
<li>TriNet Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tnet#NYSE">TNET</a>) climbed 10.6% to $105.84 after the company posted upbeat quarterly results and raised FY23 earnings forecast.</li>
<li>IMAX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/imax#NYSE">IMAX</a>) jumped 10.5% to $19.22 following strong quarterly results.</li>
<li>Textron Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/txt#NYSE">TXT</a>) gained 9.2% to $74.68 after the company reported strong second-quarter results and raised its financial outlook.</li>
<li>Lam Research Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lrcx#NASDAQ">LRCX</a>) climbed 9.1% to $700.92 following strong quarterly results.</li>
<li>Meta Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) shares rose 8.4% to $323.66 after the company reported better-than-expected second-quarter financial results.</li>
<li>Century Communities, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccs#NYSE">CCS</a>) gained 8.2% to $79.90 following strong quarterly results.</li>
<li>Helix Energy Solutions Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlx#NYSE">HLX</a>) shares rose 7.9% to $9.32 after the company reported better-than-expected second-quarter results.</li>
<li>Inseego Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insg#NASDAQ">INSG</a>) gained 7.7% to $0.7703.</li>
<li>KLA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/klac#NASDAQ">KLAC</a>) surged 7.1% to $490.52.</li>
<li>Seagate Technology Holdings plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stx#NASDAQ">STX</a>) gained 5.5% to $61.16 after posting a narrower-than-expected quarterly loss.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) shares dipped 76.3% to $0.9251 after the company said UPLIFT clinical trial of upifitamab rilsodotin did not meet primary endpoint.</li>
<li>Yellow Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yell#NASDAQ">YELL</a>) fell 55.4% to $0.4550. Yellow is preparing to file for bankruptcy, according to the Wall Street Journal.</li>
<li>Asensus Surgical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/asxc#NYSE">ASXC</a>) fell 33.3% to $0.3381 as the company reported a $10 million registered direct offering.</li>
<li>TPI Composites, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tpic#NASDAQ">TPIC</a>) fell 32.5% to $7.20 after the company lowered its 2023 forecast.</li>
<li>Warrantee Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wrnt#NASDAQ">WRNT</a>) declined 32.5% to $2.27. Warrantee recently announced pricing of $9.6m initial public offering of 2.4 million ADS at a price of $4 per ADS.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) fell 28.3% to $3.80. ABVC BioPharma announced pricing of $1.75 million registered direct offering of 500,000 shares at $3.50 per share.</li>
<li>The Shyft Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shyf#NASDAQ">SHYF</a>) fell 27.7% to $15.27 following weak quarterly sales.</li>
<li>Biohaven Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NASDAQ">BHVN</a>) dipped 27.7% to $17.19. Biohaven said the FDA informed the company it would not review NDA for troriluzole because primary endpoint was not met.</li>
<li>Oatly Group AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otly#NASDAQ">OTLY</a>) fell 26% to $1.6050 following downbeat quarterly results.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) declined 19.7% to $22.58 following weak quarterly sales.</li>
<li>MaxLinear, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mxl#NYSE">MXL</a>) fell 18.5% to $24.09 after the company posted downbeat second-quarter sales and issued weak sales guidance.</li>
<li>Inpixon (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inpx#NASDAQ">INPX</a>) tumbled 17% to $0.2083.</li>
<li>National Vision Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) fell 16.7% to $20.61. National Vision Holdings said its partnership with Walmart Inc. will be ending in 2024.</li>
<li>Perficient, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prft#NASDAQ">PRFT</a>) fell 16.4% to $75.72 after posting downbeat quarterly results.</li>
<li>Altisource Portfolio Solutions S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asps#NASDAQ">ASPS</a>) tumbled 15.4% to $5.12 following downbeat quarterly results.</li>
<li>Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) fell 14.7% to $102.18 following second-quarter results.</li>
<li>Silicon Motion Technology Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/simo#NASDAQ">SIMO</a>) shares fell 13.8% to $56.28 after jumping 25% on Wednesday.</li>
<li>Oil States International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ois#NYSE">OIS</a>) declined 13.5% to $7.59 following weak quarterly results.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) fell 12.8% to $17.87 following downbeat second-quarter results.</li>
<li>Diversified Healthcare Trust (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dhc#NASDAQ">DHC</a>) dropped 11.5% to $2.1250.</li>
<li>LendingClub Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lc#NYSE">LC</a>) fell 11.5% to $8.95 after reporting second-quarter results.</li>
<li>Columbia Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clbk#NASDAQ">CLBK</a>) declined 11% to $16.71 after posting downbeat results.</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) fell 10.7% to $36.01 after posting a wider-than-expected loss.</li>
<li>POSCO Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pkx#NYSE">PKX</a>) fell 10.1% to $114.80. POSCO Holdings recently reported quarterly financial results.</li>
<li>Willis Towers Watson Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wtw#NASDAQ">WTW</a>) fell 9% to $211.78 following weak earnings.</li>
<li>Chipotle Mexican Grill, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmg#NYSE">CMG</a>) shares tumbled 8.8% to $1,902.81 after the company missed second-quarter revenue estimates and said the benefit from menu price hikes was partially offset by elevated costs in certain ingredients.</li>
<li>Southwest Airlines Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/luv#NYSE">LUV</a>) fell 8.6% to $33.13 following mixed quarterly results. The company also reported an increase in economic fuel costs and operating expenses.</li>
<li>Edwards Lifesciences Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ew#NYSE">EW</a>) shares fell 7.7% to $84.51 following quarterly results.</li>
<li>eBay Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) declined 7.4% to $45.17. eBay reported better-than-expected earnings for its second quarter. The company said it sees third-quarter earnings per share between 96 cents and $1.01.</li>
<li>Valmont Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vmi#NYSE">VMI</a>) dropped 7.3% to $261.11 following second-quarter results.</li>
<li>Barclays PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>) shares fell 7.1% to $7.99 after the company reported second-quarter results.</li>
<li>Oceaneering International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oii#NYSE">OII</a>) shares fell 6.2% to $22.18 following weaker-than-expected quarterly results.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) shares fell 4.8% to $74.88 after reporting quarterly results.</li>
<li>Northrop Grumman Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/noc#NYSE">NOC</a>) shares declined 4.7% to $435.36 following second-quarter results. The company reported an operating margin of 10.1%, which fell from 10.8% last year.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33420556/bitcoin-ethereum-move-higher-stellar-emerges-as-top-gainer"> Bitcoin, Ethereum Move Higher; Stellar Emerges As Top Gainer </a>

Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Lipocine Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpcn#NASDAQ">LPCN</a>) shares are trading higher after the company released topline results from a Phase 2 clinical study of LPCN 1148, an oral candidate under development for the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/07/n33414045/lpcn-1148-phase-2-study-meets-primary-endpoint-in-patients-with-cirrhosis" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">clinical management of cirrhosis</a>.&nbsp;
This Phase 2 proof of concept study is an ongoing randomized placebo-controlled study in sarcopenic male patients with cirrhosis (scarring) on the liver transplant waitlist.&nbsp;
The study&#39;s primary endpoint was a change in L3-SMI at week 24. L3-SMI estimates whole-body skeletal muscle mass and is the standard for sarcopenia assessment in cirrhosis.&nbsp;
Secondary endpoints included rates of decompensation events, including hepatic encephalopathy, and participant-reported change in symptoms using the PGI-C scale.
All LPCN 1148-treated patients completed Week 24 (n=15), whereas ten of fourteen placebo patients completed Week 24.&nbsp;
1148-treated patients experienced significantly fewer cases of hepatic encephalopathy &gt; Grade 1 compared to placebo, despite the two treatment groups having a similar number of patients with a medical history of hepatic encephalopathy.&nbsp;
Patients who received active treatment reported significant improvement in symptoms as early as Week 4, which persisted through Week 24.&nbsp;
LPCN 1148 patients showed a significant increase in hemoglobin and trended towards resolving anemia, improving ascites, and reducing the number of days hospitalized.&nbsp;
CT scans suggest improved muscle quality and reduced visceral and subcutaneous fat with LPCN 1148 therapy.
LPCN 1148 was well-tolerated, with adverse event (AE) rates and severities similar to placebo; no mortality was noted in the LPCN 1148 treatment group.&nbsp;
Rates of diarrhea and nausea were low and similar in both groups. There were no cases of drug-induced liver injury.
Price Action:&nbsp;LPCN shares are up 17.1% at $5.03 on the last check Thursday.

Cantor Fitzgerald analyst Jennifer Kim reiterates Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) with a Overweight and maintains $33 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Lipocine, Maintains $33 Price Target

<h3>Gainers</h3>
<ul>
<li>Mallinckrodt (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MNK#AMEX">MNK</a>) shares rose 77.8% to $2.24 during Thursday's pre-market session. The company's market cap stands at $29.5 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) shares moved upwards by 45.79% to $0.53. The company's market cap stands at $7.9 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares rose 27.9% to $5.5. The company's market cap stands at $28.6 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares increased by 16.16% to $17.25. The company's market cap stands at $343.1 million. </li>
<li>Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares rose 15.9% to $393.91. The market value of their outstanding shares is at $30.1 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Lixte Biotech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares rose 14.72% to $4.44. The market value of their outstanding shares is at $8.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares fell 74.3% to $1.0 during Thursday's pre-market session. The market value of their outstanding shares is at $114.9 million. </li>
<li>Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) stock decreased by 24.46% to $17.98. The market value of their outstanding shares is at $1.2 billion. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares fell 9.7% to $3.06. The market value of their outstanding shares is at $77.9 million. </li>
<li>Aceragen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGN#NASDAQ">ACGN</a>) shares decreased by 7.78% to $0.83. The company's market cap stands at $6.9 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares decreased by 7.22% to $0.67. The market value of their outstanding shares is at $9.7 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock decreased by 6.93% to $2.15. The market value of their outstanding shares is at $85.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGN

CUTR

ICAD

PXMD

LPCN: 45%&nbsp;&#x7C;&nbsp;<a href="https://www.benzinga.com//node/33414045">LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis</a>
META: 10%&nbsp;&#x7C;&nbsp;<a href="http://Meta Platforms Q2 EPS $2.98 Beats $2.91 Estimate, Sales $32.00B Beat $31.12B Estimate">Meta Platforms Q2 EPS $2.98 Beats $2.91 Estimate, Sales $32.00B Beat $31.12B Estimate</a>
STM: 7.63% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/33409509">STMicroelectronics Revised FY23 Revenues Outlook to $17.25B-$17.55B, (From Prior $17.0B- $17.8B) Vs $17.3B Est</a>

Market-Moving News for July 27th

WIIM

Lipocine shares are trading higher after the company reported LPCN 1148 Phase 2 Study met its primary endpoint in patients with cirrhosis.

Lipocine Announced Topline Results From A Phase 2 Study Of LPCN 1148, For The Clinical Management Of Cirrhosis, Meeting The Primary Endpoint With The  Treatment With LPCN 1148 Increased L3 Skeletal Muscle Index Relative To Placebo

Lipocine files for $150M mixed shelf

Lipocine licenses Tlando testosterone therapy to Verity Pharma

ROMA, HPP and KRON among pre-market gainers

Lipocine (LPCN) has released an update to notify the public and investors about an entry into a material definitive agreement. On January 12, 2024,...

Lipocine Strikes Major Deal for TLANDO Franchise Rights

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to get into the biggest pre-market stock movers as we check out all of the hottest news for Thursday morning!



Moving stocks this morning are a private placement, direct listing, earnings reports, a public offering and more.



Let&rsquo;s jump into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Elevai Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/elab-stock-quote/">ELAB</a>) stock is rocketing more than 76% alongside heavy pre-market trading.</li>



<li>Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) shares are soaring over 57% after announcing a <a href="https://www.nasdaq.com/press-release/kiora-pharmaceuticals-announces-private-placement-of-up-to-approximately-%2445-million">$45 million private placement</a>.</li>



<li>FibroBiologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/fblg-stock-quote/">FBLG</a>) stock is surging more than 37% after its <a href="https://www.streetinsider.com/PRNewswire/FibroBiologics+Announces+Direct+Listing+on+NASDAQ+Under+the+Stock+Ticker+FBLG/22700034.html">direct listing yesterday</a>.</li>



<li>Global Mofy Metaverse (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmm-stock-quote/">GMM</a>) shares are gaining close to 27% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318024456&amp;type=PDF&amp;symbol=GMM&amp;cdn=292de16512a23f81c89be5480297da29&amp;companyName=Global+Mofy+Metaverse+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-02-01">release of its latest earnings report</a>.</li>



<li>NEXTracker (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxt-stock-quote/">NXT</a>) stock is increasing nearly 26% alongside its <a href="https://finance.yahoo.com/news/nextracker-reports-q3-fy24-financial-210500718.html">fiscal Q3 2024 earnings report</a>.</li>



<li>Prestige Wealth (NASDAQ:<a href="https://investorplace.com/stock-quotes/pwm-stock-quote/">PWM</a>) shares are rising over 19% on Thursday morning.</li>



<li>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock is heading more than 17% higher despite a lack of news this morning.</li>



<li>Applied UV (NASDAQ:<a href="https://investorplace.com/stock-quotes/auvi-stock-quote/">AUVI</a>) shares are getting a 17% boost after announcing <a href="https://www.nasdaq.com/press-release/applied-uv-inc.-to-develop-smart-building-technologies-for-larimar-city-a-new-luxury">a new partnership</a> to develop smart building technologies.</li>



<li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is jumping over 16% after <a href="https://www.nasdaq.com/press-release/nasdaq-determines-transcode-therapeutics-compliance-with-minimum-stockholders-equity">regaining listing compliance</a>.</li>



<li>Dare Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/dare-stock-quote/">DARE</a>) shares are up more than 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Revelation Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/revb-stock-quote/">REVB</a>) stock is plummeting close to 63% after <a href="https://www.nasdaq.com/press-release/revelation-biosciences-inc.-announces-pricing-of-%246.2-million-public-offering-2024-02">pricing a public offering</a>.</li>



<li>Infobird (NASDAQ:<a href="https://investorplace.com/stock-quotes/ifbd-stock-quote/">IFBD</a>) shares are diving 33% after announcing plans for its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318021544&amp;type=PDF&amp;symbol=IFBD&amp;cdn=61f8f5b5fc549f33cde9785c12242179&amp;companyName=Infobird+Co.+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-01-31">extraordinary general shareholder meeting</a>.</li>



<li>OneMedNet (NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/">ONMD</a>) stock is tumbling over 28% after <a href="https://investorplace.com/2024/01/why-is-onemednet-onmd-stock-up-169-today/">a recent rally</a>.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) shares are taking a more than 25% beating after announcing <a href="https://www.newsobserver.com/press-releases/article284925707.html">a reverse stock split</a>.</li>



<li>Jin Medical International (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) stock is decreasing over 18% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318021585&amp;type=PDF&amp;symbol=ZJYL&amp;cdn=b8d4f1fff46f9f35e0f349470fa605e6&amp;companyName=JIN+MEDICAL+INTERNATIONAL+LTD.&amp;formType=NT+20-F&amp;formDescription=Notification+of+inability+to+timely+file+Form+20-F&amp;dateFiled=2024-01-31">a delay to its annual report</a>.</li>



<li>Trinity Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/trib-stock-quote/">TRIB</a>) shares are dropping more than 18% after <a href="https://www.nasdaq.com/press-release/trinity-biotech-announces-q3-2023-financial-results-business-update-2024-01-31">earnings sent them higher yesterday</a>.</li>



<li>Earlyworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/elws-stock-quote/">ELWS</a>) stock is falling over 18% on Thursday.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnxa-stock-quote/">CNXA</a>) shares are dipping more than 17% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318021121&amp;type=PDF&amp;symbol=CNXA&amp;cdn=db5a8bc16df1859a949fc3cb9ac5c63e&amp;companyName=Connexa+Sports+Technologies+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-31">despite regaining listing compliance</a>.</li>



<li>Addvantage Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/aey-stock-quote/">AEY</a>) stock is slipping over 16% this morning.</li>



<li>Remark (NASDAQ:<a href="https://investorplace.com/stock-quotes/mark-stock-quote/">MARK</a>) shares close out our pre-market stock movers down more than 16% as it <a href="https://investorplace.com/2024/01/why-is-remark-mark-stock-down-45-today/">continues a retreat</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-feb-1st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Lipocine (LPCN) has released an update. The Company has released an announcement confirming the dosing regimen for their crucial study on LPCN 1154...

Lipocine Announces Key Study Dosing for Postpartum Depression Treatment

Lipocine GAAP EPS of -$3.14

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) just reported results for the fourth quarter of 2023.<ul><li>Lipocine reported earnings per share of -42 cents. This was above the analyst estimate for EPS of -47 cents.</li><li>The company reported revenue of $216,188.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/lpcn-stock-earnings-lipocine-for-q4-of-2023/">LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

Overall market sentiment has been high on Lipocine Inc (LPCN)  stock lately. LPCN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Lipocine Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPCN!See Full LPCN ReportWhat is Stock Sentiment?Se